Skip to main content

    UBS initiates coverage of Solid Biosciences LLC (SLDB) at Buy

    GNG Research Market News

    By GNG Research

    On October 15, 2026, UBS started coverage of Solid Biosciences LLC (SLDB) at Buy.

    Among five firms active over the past 90 days, five hold a bullish rating. As of October 30, 2026, 16 analysts place the consensus mean at $19.30, the median at $18.36 and the range at $14.14 to $27.30.

    For Q4 FY2026, analysts expect EPS of -$0.44 and revenue of $0. The next earnings report is scheduled for March 4, 2027.